{Reference Type}: Journal Article
{Title}: Reactivation of Epstein-Barr virus in SFTSV infected patients.
{Author}: Fang LZ;Dong YH;Yan ZJ;Zhou CM;Yu XJ;Qin XR;
{Journal}: Infect Med (Beijing)
{Volume}: 2
{Issue}: 3
{Year}: 2023 Sep
暂无{DOI}: 10.1016/j.imj.2023.04.005
{Abstract}: <B>UNASSIGNED: </B>Severe fever with thrombocytopenia syndrome (SFTS) is an emerging hemorrhagic fever caused by a tick-borne bunyavirus SFTSV with case fatality up to 30%. The reactivation of Epstein-Barr virus (EBV) has been proven to occur in individuals with various immune suppression conditions.<BR><B>UNASSIGNED: </B>Here, we diagnosed 22 SFTSV infected patients with PCR in a hospital in Shandong Province, China in 2020. To understand the consequences of SFTSV infection leading to EBV reactivation, we examined EBV reactivation in SFTSV-infected patients with PCR and RT-PCR.<BR><B>UNASSIGNED: </B>We found that EBV was reactivated in 18.2% (4/22) of SFTS patients, suggesting that EBV reactivation is common in SFTS patients. Compared with SFTS patients without EBV reactivation, SFTS patients with EBV-reactivation had a significantly lower median level of serum albumin (32.45 g/L vs. 26.95 g/L, p = 0.03) and a significantly higher median number of urine red blood cells (0 cells/μL vs. 9 cells/μL, p = 0.04).<BR><B>UNASSIGNED: </B>SFTS infection can reactivate EBV in patients, which may make the clinical condition of patients worsen.